These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35695476)

  • 1. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
    Han K; Baker M; Lovern M; Paul P; Xiong Y; Patel P; Moore KP; Seal CS; Cutrell AG; D'Amico RD; Benn PD; Landovitz RJ; Marzinke MA; Spreen WR; Ford SL
    Br J Clin Pharmacol; 2022 Oct; 88(10):4607-4622. PubMed ID: 35695476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
    Thoueille P; Saldanha SA; Schaller F; Choong E; Veuve F; Munting A; Cavassini M; Braun D; Günthard HF; Duran Ramirez JJ; Surial B; Furrer H; Rauch A; Ustero P; Calmy A; Stöckle M; Di Benedetto C; Bernasconi E; Schmid P; Marzolini C; Girardin FR; Buclin T; Decosterd LA; Guidi M;
    Clin Pharmacol Ther; 2024 Jun; 115(6):1450-1459. PubMed ID: 38519844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Han K; Wannamaker P; Lu H; Zhu B; Wang M; Paff M; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205721. PubMed ID: 35129374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.
    Yu Y; Bigos KL; Marzinke MA; Landovitz RJ; McCauley M; Ford S; Hendrix CW; Bies RR; Weld ED;
    Br J Clin Pharmacol; 2022 Oct; 88(10):4623-4632. PubMed ID: 35949044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
    Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
    Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
    Neyens M; Crauwels HM; Perez-Ruixo JJ; Rossenu S
    J Antimicrob Chemother; 2021 Nov; 76(12):3255-3262. PubMed ID: 34510179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
    Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
    Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
    Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
    Jucker BM; Fuchs EJ; Lee S; Damian V; Galette P; Janiczek R; Macura KJ; Jacobs MA; Weld ED; Solaiyappan M; D'Amico R; Shaik JS; Bakshi K; Han K; Ford S; Margolis D; Spreen W; Gupta MK; Hendrix CW; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1655-1666. PubMed ID: 34240449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir.
    Patel P; Xue Z; King KS; Parham L; Ford S; Lou Y; Bakshi KK; Sutton K; Margolis D; Hughes AR; Spreen WR
    J Antimicrob Chemother; 2020 Aug; 75(8):2240-2248. PubMed ID: 32361755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study.
    Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
    Clin Infect Dis; 2024 Aug; 79(2):477-486. PubMed ID: 38309958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
    Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
    Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.